Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
    • Medical Information
Chat Click to chat
Question Submit a question

Information Request

Lilly Rep Request

Expand contact lilly
Lilly

You are now leaving the Lilly Medical Web site

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.

  1. Medical Information Right
  2. Verzenios ® ▼ (abemaciclib) Right
  3. How to manage haematologic toxicities with Verzenios® (abemaciclib) in early breast cancer
Search abemaciclib information
Search Medical Information


Tips for searching:

• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences

Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.

Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

How to manage haematologic toxicities with Verzenios® (abemaciclib) in early breast cancer

Dose modification is recommended for patients who develop Grade 3 or Grade 4 haematologic toxicities. Grade 1 or Grade 2 neutropenia does not require dose modification.

UK_cFAQ_ABE026_HEMATOLOGIC_ADVERSE_EVENTS_EBC
UK_cFAQ_ABE026_HEMATOLOGIC_ADVERSE_EVENTS_EBC
en-GB

Management recommendations for haematologic toxicities with abemaciclib

Please find

  • dose modification and management recommendations in Dose modification and management recommendations for haematologic toxicities
  • Common Terminology Criteria for Adverse Events (CTCAE) Grade definitions for haematologic toxicities in NCI CTCAE Grade Definitions
    Dose modification and management recommendations for haematologic toxicities1